Figure 4.
Comparison of drug sensitivity between BCR::ABL1–positive imatinib-resistant PDX cell line and imatinib-sensitive or BCR::ABL1–negative cell line. (A) Comparison of all tested drugs with an AUC of <400 between BCR::ABL1–positive imatinib-sensitive cell line (M4A4-BA1) and BCR::ABL1–positive imatinib-resistant cell line (M4A3-BA1). (B) Comparison of all tested drugs with an AUC of <400 between BCR::ABL1–negative cell line (M4A1-M2B9) and BCR::ABL1–positive resistant cell line (M4A3-BA1). The red area shows the 95% confidence interval (CI); dots in red are outside the 95% CI; dots in blue are TKIs inside the 95% CI.

Comparison of drug sensitivity between BCR::ABL1–positive imatinib-resistant PDX cell line and imatinib-sensitive or BCR::ABL1–negative cell line. (A) Comparison of all tested drugs with an AUC of <400 between BCR::ABL1–positive imatinib-sensitive cell line (M4A4-BA1) and BCR::ABL1–positive imatinib-resistant cell line (M4A3-BA1). (B) Comparison of all tested drugs with an AUC of <400 between BCR::ABL1–negative cell line (M4A1-M2B9) and BCR::ABL1–positive resistant cell line (M4A3-BA1). The red area shows the 95% confidence interval (CI); dots in red are outside the 95% CI; dots in blue are TKIs inside the 95% CI.

Close Modal

or Create an Account

Close Modal
Close Modal